Loading...
XSHG600211
Market cap1.65bUSD
Dec 25, Last price  
37.31CNY
1D
1.44%
1Q
10.36%
Jan 2017
-3.28%
Name

Tibet Rhodiola Pharmaceutical Holding Co

Chart & Performance

D1W1MN
XSHG:600211 chart
P/E
15.01
P/S
3.84
EPS
2.48
Div Yield, %
4.02%
Shrs. gr., 5y
5.09%
Rev. gr., 5y
24.98%
Revenues
3.13b
+22.69%
182,662,148696,482,195861,841,830823,237,884991,069,9641,109,621,0751,110,729,2681,079,038,0191,221,385,4211,402,221,1591,668,036,0411,382,755,815796,806,691915,625,7171,027,879,2101,256,021,9571,373,105,1052,138,586,5522,554,609,0663,134,328,350
Net income
801m
+116.56%
6,081,28203,077,27406,486,26419,087,06723,556,57620,514,32930,530,18127,153,18020,979,87091,635,772198,289,475229,645,747215,606,211312,321,254418,095,830208,938,062369,839,847800,913,981
CFO
1.08b
+29.23%
26,904,34318,918,70433,629,555021,457,33717,884,2571,900,16912,090,45256,200,572279,222,0050133,930,272250,204,85991,457,114289,217,375489,592,488428,165,608366,531,412837,377,0381,082,137,896
Dividend
Aug 29, 20240.967 CNY/sh
Earnings
Apr 16, 2025

Profile

Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. It offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. The company was founded in 1999 and is based in Lhasa, China.
URL
http://www.xzyy.cn
IPO date
Jul 21, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,134,328
22.69%
2,554,609
19.45%
2,138,587
55.75%
Cost of revenue
1,968,341
1,691,534
1,483,428
Unusual Expense (Income)
NOPBT
1,165,987
863,075
655,159
NOPBT Margin
37.20%
33.79%
30.64%
Operating Taxes
87,950
88,115
41,824
Tax Rate
7.54%
10.21%
6.38%
NOPAT
1,078,037
774,960
613,334
Net income
800,914
116.56%
369,840
77.01%
208,938
-50.03%
Dividends
(482,983)
(83,803)
(126,448)
Dividend yield
3.07%
0.94%
0.97%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
499,985
487,103
536,789
Long-term debt
1,125
2,289
3,725
Deferred revenue
25,855
27,527
30,501
Other long-term liabilities
1
2
Net debt
(1,475,303)
(1,442,928)
(761,767)
Cash flow
Cash from operating activities
1,082,138
837,377
366,531
CAPEX
(21,689)
Cash from investing activities
(848,390)
Cash from financing activities
(485,895)
376,670
FCF
881,226
1,054,180
(17,734)
Balance
Cash
2,375,127
1,932,320
1,302,280
Long term investments
(398,713)
Excess cash
1,819,697
1,804,590
1,195,351
Stockholders' equity
2,118,112
1,775,263
1,389,512
Invested Capital
2,080,889
1,709,192
1,969,238
ROIC
56.89%
42.14%
32.98%
ROCE
29.88%
24.67%
20.60%
EV
Common stock shares outstanding
322,351
247,938
247,938
Price
48.80
35.86%
35.92
-31.40%
52.36
-22.18%
Market cap
15,730,742
76.63%
8,905,927
-31.40%
12,982,025
-22.18%
EV
14,284,471
7,482,030
12,234,920
EBITDA
1,227,728
932,316
736,607
EV/EBITDA
11.63
8.03
16.61
Interest
11,594
14,358
4,329
Interest/NOPBT
0.99%
1.66%
0.66%